Feb 8 (Reuters) - Medtronic Inc:
* Issues statement on district court ruling regarding CoreValve
* Says court also affirmed the jury's verdict and damages award against
Medtronic on patent infringement
* Says the court also affirmed the jury's verdict and damages award against
Medtronic on patent infringement
* Says Medtronic disagrees with this conclusion and plans to appeal.
* Says court's ruling has no impact on the Medtronic CoreValve U.S. pivotal
trial, which began in December
* Says Medtronic disagrees with this conclusion and plans to appeal
* Says court also denied edwards' request for enhanced damages
* Says does not anticipate any interruption to supply of its CoreValve system
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Issues statement on district court ruling regarding CoreValve
* Says court also affirmed the jury's verdict and damages award against
Medtronic on patent infringement
* Says the court also affirmed the jury's verdict and damages award against
Medtronic on patent infringement
* Says Medtronic disagrees with this conclusion and plans to appeal.
* Says court's ruling has no impact on the Medtronic CoreValve U.S. pivotal
trial, which began in December
* Says Medtronic disagrees with this conclusion and plans to appeal
* Says court also denied edwards' request for enhanced damages
* Says does not anticipate any interruption to supply of its CoreValve system
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.